Australia markets close in 46 minutes

JCR Pharmaceuticals Co., Ltd. (JCRRF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
5.22-0.98 (-15.81%)
At close: 09:42AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 461.67M
Enterprise value 493.33M
Trailing P/E 18.76
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.41
Price/book (mrq)2.00
Enterprise value/revenue 1.82
Enterprise value/EBITDA 10.34

Trading information

Stock price history

Beta (5Y monthly) -0.01
52-week change 3-44.99%
S&P500 52-week change 325.87%
52-week high 310.11
52-week low 35.22
50-day moving average 35.22
200-day moving average 38.11

Share statistics

Avg vol (3-month) 31
Avg vol (10-day) 3N/A
Shares outstanding 5124.8M
Implied shares outstanding 6124.93M
Float 873.39M
% held by insiders 143.26%
% held by institutions 115.75%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.13
Forward annual dividend yield 42.47%
Trailing annual dividend rate 320.00
Trailing annual dividend yield 3322.58%
5-year average dividend yield 4N/A
Payout ratio 445.54%
Dividend date 3N/A
Ex-dividend date 427 Sept 2024
Last split factor 24:1
Last split date 330 Sept 2020

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 12.85%
Operating margin (ttm)-3.03%

Management effectiveness

Return on assets (ttm)4.77%
Return on equity (ttm)10.17%

Income statement

Revenue (ttm)42.87B
Revenue per share (ttm)343.54
Quarterly revenue growth (yoy)19.70%
Gross profit (ttm)N/A
EBITDA 10.73B
Net income avi to common (ttm)5.51B
Diluted EPS (ttm)0.28
Quarterly earnings growth (yoy)70.10%

Balance sheet

Total cash (mrq)18.76B
Total cash per share (mrq)150.28
Total debt (mrq)23.3B
Total debt/equity (mrq)41.26%
Current ratio (mrq)1.91
Book value per share (mrq)450.11

Cash flow statement

Operating cash flow (ttm)9.31B
Levered free cash flow (ttm)4.25B